text:
Drug and Alcohol Dependence
- Easter Woods
- 3 years ago
- Views:
1 Drug and Alcohol Dependence 108 (2010) Contents lists available at ScienceDirect Drug and Alcohol Dependence journal homepage: Mortality among drug users after discharge from inpatient treatment: An 8-year prospective study Edle Ravndal a,, Ellen J. Amundsen b a University of Oslo, SERAF/Norwegian Centre for Addiction Research, Ullevål Hospital, N-0407 Oslo, Norway b SIRUS/Norwegian Institute for Alcohol and Drug Research, PO Box 565 Sentrum, N-0105 Oslo, Norway article info abstract Article history: Received 18 September 2009 Received in revised form 12 November 2009 Accepted 17 November 2009 Keywords: Mortality Overdoses Drug use Inpatient Treatment Prospective Background: Drug users who are leaving/completing inpatient medication-free treatment may, like drug users released from prison, have an elevated risk of dying from fatal overdoses. This is mainly explained by their low drug tolerance. Methods: Two hundred and seventy-six drug users who had been admitted to 11 inpatient facilities in Norway, were followed prospectively after discharge from treatment during an 8-year period ( ). The following instruments were used: EuropASI, SCL-25 and MCMI II. Information on deaths and causes of death were obtained from the National Death Register. Results: A total of 36 deaths were registered after discharge from treatment during the observation period, of which 24 were classified as overdose deaths. During the first 4 weeks after discharge six persons died, yielding an unadjusted excess mortality of 15.7 (rate ratio) in this period (CI ). All were dropouts and all deaths were classified as opiate overdoses. There was no significant association between time in index treatment and mortality after discharge, nor did any background characteristics correlate significantly with elevated mortality shortly after discharge. Conclusions: The elevated risk of dying from overdose within the first 4 weeks of leaving medicationfree inpatient treatment is so dramatic that preventive measures should be taken. More studies from similar inpatient programmes are needed in order to obtain systematic knowledge about determinants of overdose deaths shortly after leaving treatment, and possible preventive measures Elsevier Ireland Ltd. All rights reserved. 1. Introduction It is well documented that there is a high mortality rate among drug users, and that death by overdose is common cause of death in that group (Clausen et al., 2008; Darke et al., 2007; Davoli et al., 2007; Bargagli et al., 2006; Johnson et al., 2005; Gossop et al., 2002). Actually, deaths from opiate overdose comprise the vast majority of all drug-related deaths (Strang et al., 2008; Darke and Zador, 1996). One situation of the utmost importance in relation to overdose deaths, and where the prevalence of overdoses seems to be especially high, is in the period of time immediately after release from prison. Numerous studies from different countries and cultures show that drug users who leave prison and start using drugs again within 2 4 weeks after release, have a significantly higher mortality from primarily overdoses than the rest of the drug use population (Darke, 2007; Farell and Marsden, 2007; Ødegård et al., Corresponding author. Tel.: /76; fax: address: (E. Ravndal). 2009). This is mainly explained by a reduction in their drug tolerance. Substitution treatment for opiate users is now common in most western countries, but medication-free inpatient treatment (MFIT) and therapeutic communities (TCs) are also common alternatives in the same countries. TC is a well-established treatment modality internationally, aiming at abstinence and full rehabilitation (Broekaert et al., 1999). One main characteristic of the programmes is that they are long-term, i.e. they usually last for 1 2 years. Dropout rates have always been high (60 70%) in most of these programmes (Broekaert et al., 1999; Ravndal et al., 2005). One may therefore assume that clients who are dropouts and relapse shortly after leaving treatment may, like drug users released from prison, have a greater risk of taking fatal overdoses. However, even those who complete treatment are in much the same situation due to reduced tolerance. A 1 year follow-up study investigated opiate clients receiving detoxification as part of a 28 day inpatient treatment programme. The main finding showed a clustering of deaths from overdose in the group of patients characterized by loss of tolerance, who had successfully completed treatment (Strang et al., 2003). Most treatment studies show that the longer clients stay in /$ see front matter 2009 Elsevier Ireland Ltd. All rights reserved. doi: /j.drugalcdep
2 66 E. Ravndal, E.J. Amundsen / Drug and Alcohol Dependence 108 (2010) treatment, the better the outcome (Simpson et al., 1997; Hser et al., 1988). There is therefore reason to believe that the longer clients stay in treatment, the lower the chances of relapse and death by overdose. Some studies mention that dropping out of both MFIT/TCs and substitution treatment is a commonly observed antecedent of fatal opioid overdose. However, these studies have not analysed the length of time elapsed between leaving treatment and death (Quaglio et al., 2001; Preti et al., 2002). Except for one study by Davoli et al. (2007), hardly any research on MFIT/TCs has looked into this phenomenon. Davoli et al. (2007) show that retention in both in- and outpatient treatment for opiate users helps to protect against overdose mortality. They also demonstrate that the hazard ratio of overdose death was 26.6 during the month immediately following treatment, as against 7.3 in the subsequent period. Norway is one of the countries in Europe with the highest overdose-related mortality rate. From 1991 to 2001, there was a steady increase in overdose and unnatural deaths among drug users in Norway (Rusmidler i Norge/Alcohol and Drugs in Norway, 2008). The peak year was in 2001 with 405 registered deaths, followed by a drop in 2003 (255 deaths) and a stable situation until 2006 (251 deaths). 1 Substitution treatment, which was introduced nationally under rather strict rules in Norway in 1998, and other measures to establish low thresholds do not seem to have reduced mortality sufficiently. Effective, new prevention strategies for reducing overdose deaths should be based on studies that investigate special settings and/or periods of time featuring a particularly high risk of mortality. We wanted to study whether the elevated mortality risk following release from prison also occurs when drug users leave MFIT/TCs. A prospective study was conducted on 276 drug users who had been admitted to 11 MFIT/TCs in Norway, with a mean observation period of 8 years. Our main questions for investigation were: (1) What was the mortality rate during the 8-year period following discharge from MFIT/TC? (2) Was there an increased risk of overdose death/unnatural death shortly after leaving treatment? (3) What were the main causes of death? (4) Do the length of time spent in index treatment or the dropout rate correlates with the risk of overdose death/unnatural death? (5) Are client characteristics associated with increased risk of death by overdose? 2. Materials The study is a prospective, naturalistic study of 300 subjects who consecutively entered 11 MFIT/TCs in Oslo and surrounding counties between January 1998 and August None of the treatment programmes were administered through a prison setting. Participation in the study was voluntary. Twelve clients left treatment before the interview took place, and 12 were unwilling to take part in the study. These clients did not differ significantly from the rest (n = 276) in terms of background characteristics. The modalities consist of two hierarchical (HTC) and nine democratic therapeutic communities (DTC). All modalities had abstinence and full rehabilitation as their primary goal and different forms of aftercare were included. While in treatment any use of drugs was not tolerated. However, no clients were forced to quit treatment involuntary because of drug use as long as they tried again to adhere to the treatment rules. Except for the two HTCs, and one DTC for women only that was based on the 12-step model (AA), treatment in the other facilities was based on no specific ideology or philosophy. 3. Methods All clients were examined during the first 2 weeks of treatment. They were personally interviewed and rated using the European Addiction Severity Index (EuropASI) (Kokkevi and Hartgers, 1994). At the same time, they completed two selfreport questionnaires: The Millon Clinical Multiaxial Inventory II (MCMI II) (Millon, 1987) and the Symptom Checklist 25 (SCL-25) (Derogatis et al., 1974) The European Addiction Severity Index (EuropASI) The EuropASI is a personal, structured interview that is designed for clinical as well as research purposes. It covers seven areas: medical status, employment and support status, drug and alcohol use, legal status, family history, family and social relationships and psychiatric status. The reliability and validity of EuropASI is well documented (Hodgins and El-Guebaly, 1992; Leonhard et al., 2000). Two people from the project group interviewed half the sample. Six staff members from different treatment facilities interviewed the other half. All interviewers were trained at an authorised EuropASI course before interviewing the clients The Symptom Checklist 25 (SCL-25) The SCL-25 is a 25-point self-report inventory that assesses symptoms of depression and anxiety. The mean overall score is called the General Symptom Index (GSI), and it is used as a measure of a person s total symptoms the week prior to the interview. Clients with scores of 1.0 and above are considered cases. The analyses used the depression and anxiety scales, as well as the GSI index The Millon Clinical Multiaxial Inventory II (MCMI II) The MCMI II is a self-report instrument with 175 true/false items measuring 13 personality profiles and nine clinical syndromes according to the DSM-III-R system. Scores on the MCMI are reported as base rate (BR) scores that are transformed raw scores adjusted for gender differences. According to international practice, clients who score 85 or above are considered to have a personality disorder (PD). This study only used the personality profiles and the PD diagnosis in the analyses National Death Register Information on deaths and causes of death (ICD coded) were obtained from the National Death Register kept by Statistics Norway. Inclusion of deaths in the overdose category is based on ICD codes F11 and X42 with opioid use as the main cause of death Leaving treatment Leaving treatment was defined as either voluntary dropout or completion of treatment. Dropout and completion of treatment were defined according to criteria set by the treatment staff in collaboration with the research group. The main criteria for successful completion of treatment were completion of all phases of the programme, full abstinence from substances and active involvement in some kind of psychosocial rehabilitation Definition of the time window The only study we found that examines the risk of premature deaths shortly after leaving treatment used a 4-week window (Davoli et al., 2007). In the prison literature, the time window for a high risk of death varies between studies, ranging from 1 to 4 weeks or even longer (Ødegård et al., 2009). In this study, we chose a time window of the first 4 weeks after dropping out or completing treatment, in accordance with the study of Davoli et al. (2007) Statistical analyses The number of deaths divided by the number of 100 person-years at risk (mortality rate) is specified, with confidence intervals in parentheses. The excess risk immediately after discharge from treatment was estimated by looking at the crude rate ratio for the first 4-week period compared with the rest of the follow-up period. Proportional hazard (Cox) regression was used to analyse the correlation between time to death and factors hypothesised to be associated with the risk of death. The proportionality assumptions were tested. Then the crude rate ratio for the 4- week period compared with the rest of the follow-up period was adjusted using Mantel Haenszel methodology (Clayton and Hills, 1998). The adjustment was carried out bivariately for factors assumed to affect mortality or showing significant effects in the Cox regression. 4. Results 1 The WHO ICD coding system versions 9 (code 304) and 10 (a combination of F, X and T codes were used in accordance with the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) standard protocol for unintentional death) defined these figures Sample characteristics Seventy percent of the sample was male and the mean age at intake to index treatment was 31 years (SD = 6.4; range: 17 49
3 E. Ravndal, E.J. Amundsen / Drug and Alcohol Dependence 108 (2010) Table 1 Deaths by time after discharge from inpatient treatment, risk per 100 person-years (n = 36). Time after discharge Deaths Years at risk Risk of death CI (95%) 4 weeks From 5 weeks to ½ year From ½ year to 1 year Second year Third year Fourth year Fifth year Sixth year or more Total Table 3 Unadjusted effects of background and treatment variables on risk of death after discharge from inpatient treatment (N = 276). Hazard ratio CI (95%) Age (years) Alcohol abuse >5 years (yes no) Use of heroin (yes no) Use of syringes (yes no) Overdoses (yes no) Suicide attempts (yes no) In prison >12 months (yes no) Treatment model (DTC vs. HTC) Number of months in treatment Dropout (yes no) years). During the last 30 days before intake to treatment, 73% had used heroin, 36% amphetamines, 54% benzodiazepines and 81% had used syringes. The mean number of self-reported overdoses before entering index treatment was 4.8 (SD = 10.9, range: 0 99), and 59% reported one or more suicide attempts. Forty-eight percent were cases on GSI as measured by SCL-25, and 75% had a personality disorder (MCMI). Fifty-nine percent had previously been in inpatient treatment one or more times, and 30% had been in prison for a total of more than 1 year. Altogether males had spent significantly more time in prison than females (17.6 months vs. 4.3 months, p < 0.000). They also had significantly higher scores on the MCMI antisocial (p < 0.01), while females had significantly more suicide attempts (p < 0.05), had used significantly more benzodiazepines (p < 0.05) and had significantly higher scores on the MCMI histrionic (p < 0.01). There were no gender differences in the depression or anxiety scores as measured by SCL Time in treatment and dropping out Mean time in index treatment for all clients was 54 weeks (SD = 46.2; range: weeks). Forty-one percent completed the programme and 59% were dropouts. There were no significant gender differences in dropout from treatment Deceased clients and mortality Of the 276 clients in the study, a total of 36 deaths were registered during the 8-year period after discharge from treatment. Only three of these were women. This represents a mortality rate of 2.1 (CI ) per 100 person-years, 3.1 for males (CI ) and 0.6 for females (CI ) (Table 1). During the first 4 weeks after discharge from MFIT/TC, six persons died (two women), yielding an unadjusted excess mortality (rate ratio) of 15.7 (CI ) in this period. They were all dropouts. These six deaths occurred during the first 3 weeks and were classified as opiate overdoses. Altogether, there were 24 overdose deaths, 7 violent deaths (including traffic accidents), and 5 from causes unknown. Among the 36 deceased persons, 29 (69%) had taken overdoses and 19 (53%) had been in prison longer than 1 year before index treatment. Altogether, 13 (36%) had been in TC and 23 (64%) in DTC. Of the 36 persons, 25 (69%) were dropouts. The only signifi- cant difference in mortality was for those who had stayed a total of more than 1 year in prison (4.2 per 100 person-years) (CI ) compared with those who had shorter or no stays (1.5 per 100 person-years) (CI ). As to psychopathology as measured by MCMI and SCL-25, there was no difference in mortality between the deceased and the other subjects. The association between time in index treatment and mortality after discharge showed no significant pattern. It is of interest, however, that no deaths occurred among the 22 subjects who stayed in treatment continuously for more than 2 years (Table 2) Unadjusted effects of client characteristics on death after discharge Using Cox regression, very few of the client characteristics before entering MFIT/TC were associated with mortality upon discharge from treatment (Table 3). Having spent more than 12 months in prison altogether was the only significant predictor. Gender could not be included in the Cox regressions because of the small number (3) of deceased females (just one of the women died after the 4-week period), and the variable did not meet the assumption of proportional hazards Adjusted associations of client background and treatment variables with excess mortality during the 4-week period after discharge We used the Mantel Haenszel method to adjust for possible correlations of background and treatment variables with excess mortality during the first 4 weeks after discharge from treatment compared with the rest of the period after discharge. None of the variables, i.e. age, time in index treatment, time spent in prison, number of self-reported overdoses or alcohol abuse, had any significant association with excess mortality during the first 4 weeks after discharge from treatment. 5. Discussion The main finding of the study was the significantly higher risk of dying from overdose during the first 4 weeks after leaving treatment, as compared with the rest of the 8-year observation period. This concurs with the study made by Davoli et al. (2007), which Table 2 Deaths after discharge by time in inpatient treatment, risk per 100 person-years (N = 276, n = 36). Time in treatment Number of persons Deaths Years at risk after discharge Risk of death CI (95%) Up to ½ year From ½ year to 1 year From 1 year to 1½ year From 1½ year to 2 years More than 2 years (0)
4 68 E. Ravndal, E.J. Amundsen / Drug and Alcohol Dependence 108 (2010) also used a 4-week window to assess the risk of excess mortality shortly after leaving treatment. The association between time in index treatment and mortality after discharge showed no significant pattern. No deaths, however, occurred among the 22 subjects who stayed in index treatment continuously for more than 2 years. There was no significant difference in risk of death for dropouts and completers. Thirty-six drug users died during the 8-year observation period, representing a mortality rate of 2.1 per 100 person-years. Only three of the deceased were females. This harmonises with other studies, showing that males have a significantly higher risk of death (Darke et al., 2007; Gossop et al., 2002; Ødegård et al., 2007; Clausen et al., 2008). There was no significant association between treatment length and risk of death after discharge from inpatient treatment. However, there was a tendency for people with longer stays to have a lower risk of death. This question is of great clinical importance and needs to be investigated further in studies based on larger samples. There was no significant difference in mortality between dropouts and completers. This clearly indicates that successful completion of treatment at one point in time does not prevent subsequent relapse and possible death later on (Strang et al., 2003). However, all deaths in the 4-week period after discharge were among the dropouts. The lack of opiate tolerance, probably in combination with resignation caused by dropping out of treatment makes this situation very risky. Dropouts from inpatient treatment should therefore be a special target group for special interventions, which should be planned in advance. No single characteristic was independently associated with elevated mortality shortly after discharge. However, there was a tendency for total time spent in prison before index treatment to be a predictor of death after discharge. One possible explanation may be that this group of males was more antisocial and prone to take risks, and both of these factors could lead to more crime and a more reckless lifestyle, including death by overdose. If this is the case, it is in line with another Norwegian study of drug users in treatment in which being a male, a case on the MCMI antisocial and having spent a long overall time in prison were all significant predictors of death 5 years later (Ravndal and Vaglum, 1998). Our findings underline the need to introduce preventive measures among drug users leaving treatment in non-substitution programmes such as MFIT/TCs. As Darke (2007) underlines in a comment to the high risk of dying after release from prison: If such high rates of death were occurring among young, ambulatory patients released from hospital there would be a scandal. However, there are not always easy solutions at hand. Successful preventive measures are not easy to implement in any population group. For a myriad of good reasons, the behaviour of heroin users is often quite difficult to change. A recent qualitative study of experiences with overdoses among Swedish heroin users is instructive. The participants were aware of many of the common risk factors for overdoses. In spite of this, most overdoses occurred as a result of conscious risk-taking behaviour. The search for the ultimate rush, as well as severe abstinence, anxiety and depression, feelings of indifference and dependency, and an unsafe, stressful environment were examples of factors that led to a decrease in considering risks (Richert and Svensson, 2008). The authors conclude that heroin overdoses cannot be fully understood simply by defining a variety of isolated factors. It is more important to better understand how heroin users understand and evaluate the risk they are taking, and what circumstances and which emotions and motives influence risk-taking that may lead to overdose. Nonetheless, it is important for treatment providers and the healthcare authorities to seriously try to implement preventive strategies for clients in MFIT/TCs. As regards the drug users, different strategies are possible. First, it is important to ensure that clients in MFIT/TCs take part as early as in overdose prevention awareness programmes with particular emphasis on the nature of overdose risk in the event of leaving treatment prematurely. Studies show that drug users are an overlooked potential workforce, interested in and willing to attend preventive training courses and to apply such knowledge when necessary (Strang et al., 2008; Baca and Grant, 2007; Lagu et al., 2006). Second, programmes to prevent fatal overdoses may be established and evaluated in the community, using resuscitation techniques as well as opioid antagonist medication such as naloxone (Strang et al., 2008; Piper et al., 2007; Galea et al., 2006). Since 1980s, naloxone has been available as an over-the-counter medication in Italy and distributed through low-threshold services in Berlin, Germany; Jersey, UK; and San Francisco, USA (Dettmer et al., 2001). Preliminary results indicate lifesaving events through peer administration of naloxone (Strang et al., 2008; Seal et al., 2005). The above-mentioned research is still a young but promising field. Surely, a wide range of preventive strategies will have to be applied if overdose deaths are going to be reduced. Preventive strategies must be planned and carried out in treatment and community settings alike, and in continuous cooperation between active users of heroin, clients in treatment, the families of heroin users, and healthcare and social service authorities. Only broad cooperation between all involved parties can help ensure that fewer heroin users, old and young alike, die from accidental or planned overdoses. No final conclusions can be drawn concerning the lack of association between time in treatment and fatal overdose, or between client characteristics and premature death. There are some tendencies in the material, but the study needs to be repeated using a larger sample to be able to conclude whether these are just tendencies or can be stated as important findings. That being said, the strength of the study lies in the long observation time and the quality of the data. 6. Conclusion In conclusion, the main finding of the study is the significantly higher risk of dying from overdose within the first 4 weeks of leaving medication-free inpatient treatment. This finding is in itself so dramatic that measures should be taken immediately to try to prevent this kind of overdose deaths. It strongly suggests a potential for structural intervention including, but not limited to, continuous surveillance and active use of various peers and networks. No particular client characteristics were associated with death after discharge, except that the majority was male. This may be due to our small study sample. Therefore more studies are needed from similar inpatient programmes in order to obtain more systematic knowledge about determinants of overdose deaths shortly after leaving treatment, and how preventive measures can best be implemented. Role of funding source Funding of the study was provided by the Norwegian Research Council and the Norwegian Institute for Alcohol and Drug Research. The funders did not have any role in the study design; the collection, analysis, and interpretation of the data, and the writing of the paper. Contributors Edle Ravndal and Ellen Amundsen designed the study, executed the statistical analyses and wrote the manuscript. Edle Ravndal is the Principal Investigator of the study. Both authors have read and approved this final version of the manuscript.
5 E. Ravndal, E.J. Amundsen / Drug and Alcohol Dependence 108 (2010) Conflict of interest There are no conflict of interest. Acknowledgements The authors appreciate the expert consultations with Professor Michael Gossop leading to writing up the paper. Only the authors are responsible for the final conclusions and in the decision to submit the manuscript for publication. References Baca, C.T., Grant, K.J., What heroin users tell us about overdose. J. Addict. Dis. 26, Bargagli, A.M., Hickman, M., Davoli, M., Perucci, C.A., Schifano, P., Buster, M., Brugal, T., Vincente, J., Group, C.E., Drug-related mortality and its impact on adult mortality in eight European countries. Eur. J. Public Health 16, Broekaert, E., Raes, V., Kaplan, C.D., Coletti, M., The design and effectiveness of therapeutic community research in Europe: an overview. Eur. Addict. Res. 5, Clausen, T., Andersen, K., Waal, H., Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 94, Clayton, D., Hills, M., Statistical Models in Epidemiology. Oxford University Press, Oxford. Dettmer, K., Saunders, B., Strang, J., Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. BMJ 322, Darke, S., From the can to the coffin: deaths among recently released prisoners. Addiction 103, Darke, S., Mattick, R., Degenhardt, L., Mortality Amongst Illicit Drug Users. Cambridge University Press, Cambridge. Darke, S., Zador, D., Fatal heroin overdose : a review. Addiction 91, Davoli, M., Bargagli, A.M., Perccci, C.A., Schifano, P., Belleudi, V., Hickman, M., Salamina, G., Diecidue, R., Vigna-Taglianti, F., Faggiano, F., Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multisite prospective cohort study. Addiction 102, Derogatis, L.R., Lipman, R.S., Rickels, K., Uhlenhuth, E.H., Covi, L., The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav. Sci. 19, Farell, M., Marsden, J., Acute risk of drug-related death among newly released prisoners in England and Wales. Addiction 103, Galea, S., Worthington, N., Piper, T.M., Nandi, V.V., Curtis, M., Rosenthal, D.M., Provision of naloxone to injection drug users as an overdose prevention strategy: early evidence from a pilot study in New York City. Addict. Behav. 31, Gossop, M., Stewart, D., Treacy, S., Marsden, J., A prospective study of mortality among drug misusers during a 4-year period after seeking treatment. Addiction 97, Hodgins, D.C., El-Guebaly, N., More data on the Addiction Severity Index. Reliability and validity with the mentally III substance abusers. J. Nerv. Ment. Dis. 180, Hser, Y.I., Anglin, M.D., Chou, C., Evaluation of drug abuse treatment: a repeated measures design assessing methadone maintenance. Eval. Rev. 12, Johnson, J.E., Finney, J.W., Moos, R.H., Predictors of 5-year mortality following inpatient/residential group treatment for substance abuse disorders. Addict. Behav. 30, Kokkevi, A., Hartgers, C., European Addiction Severity Index (EuropASI). Cost, A6. Lagu, T., Anderson, B.J., Stein, M., Overdoses among friends: drug users are willing to administer naloxone to others. J. Subst. Abuse Treat. 30, Leonhard, C.L., Mulvey, K., Gastfriend, D.R., Shwartz, M., The Addiction Severity Index. A field study of internal consistency and validity. J. Subst. Abuse Treat. 18, Millon, T., Millon Clinical Multiaxial Inventory-II. National Computer Systems, Minneapolis, US. Ødegård, E., Amundsen, E.J., Kielland, K.B., Fatal overdoses and deaths from other causes in a cohort of Norwegian drug abusers a competing risk approach. Drug Alcohol Depend. 89, Ødegård, E., Amundsen, E.J., Kielland, K.B., Kristoffersen, R., The contribution of imprisonment and release to fatal overdose and unnatural death among a cohort of Norwegian drug abusers. Addict. Res. Theory, doi: / Piper, T., Rudenstine, S., Stancliff, S., Sherman, S., Nandi, V., Clear, A., Galea, S., Overdose prevention for injection drug users: lessons learned from naloxone training and distribution programs in New York City. Harm Reduct. J. 4, 3. Preti, A., Miotto, P., De Coppi, M., Deaths by unintentional illicit drug overdose in Italy, Drug Alcohol Depend. 66, Quaglio, G., Talamini, G., Lechi, A., Venturini, L., Lugoboni, F., Mezzelani, P., Study of 2708 heroin-related deaths in north-eastern Italy to establish the main cause of death. Addiction 96, Ravndal, E., Vaglum, P., Psychopathology, treatment completion and 5 years outcome: a prospective study of drug abusers. J. Subst. Abuse Treat. 15, 1 8. Ravndal, E., Vaglum, P., Lauritzen, G., Completion of long-term inpatient treatment of drug abusers: a prospective study from 13 different units. Eur. Addict. Res. 11, Richert, T., Svensson, B., Med livet som innsats injeksjonsmissbruk, risktagande och överdoser (In English: With your life on the line injecting, risk-taking and overdoses). NAT (Nordic Journal of Alcohol and Drugs) 25, Rusmidler i Norge, Drugs and Alcohol in Norway. Norwegian Institute for Alcohol and Drug Research, Oslo. Seal, K.H., Thawley, R., Gee, L., Bamberger, J., Kral, A.H., Ciccarone, D., Downing, M., Edlin, B.R., Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death. J. Urban Health 82, Simpson, D.D., Joe, G.W., Rowan-Szal, G.A., Drug abuse retention and process effects on follow-up outcomes. Drug Alcohol Depend. 47, Strang, J., McCambridge, J., Best, D., Beswick, T., Bearn, J., Rees, S., Gossop, M., Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow-up study. BMJ 326, Strang, J., Manning, V., Mayet, S., Best, D., Titherington, E., Santana, L., Offor, E., Semmler, C., Overdose training and take-home naloxone for opiate users: prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses. Addiction 103,
A Cost-Effectiveness Study of Toronto Public Health s Preventing Overdose in Toronto (POINT) Program
A Cost-Effectiveness Study of Toronto Public Health s Preventing Overdose in Toronto (POINT) Program Dima Saab, Lady Bolongaita, Jennifer Innis 2013 Annual CAHSPR Conference May 29, 2013: Vancouver, B.C.More information
A 10-year follow-up study of drug users in treatment. Grethe Lauritzen, SIRUS
A 10-year follow-up study of drug users in treatment Grethe Lauritzen, SIRUS A prospective co-hort study 10-year observation period (1998-2009) 481 clients interviewed in 20 treatment facilities in andMore information
What are the outcomes for assessing drug treatment? A review of long-term observational studies on the treatment of opioid dependence
What are the outcomes for assessing drug treatment? A review of long-term observational studies on the treatment of opioid dependence Lucas Wiessing & Marica Ferri, EMCDDA Background Drug use and addiction,More information
The treatment of heroin dependence presents
Residential Rehabilitation for the Treatment of Heroin Dependence: Sustained Heroin Abstinence and Drug-Related Problems 2 Years After Treatment Entrance Shane Darke, PhD, Anna Williamson, BPsych Hons,More information
The VEdeTTE cohort study: Effectiveness of treatments for heroin addiction in retaining patients and reducing mortality
The VEdeTTE cohort study: Effectiveness of treatments for heroin addiction in retaining patients and reducing mortality Federica Vigna-Taglianti www.oed.piemonte.it Piedmont Centre for Drug Addiction EpidemiologyMore information
Trends in deaths related to drug misuse in England and Wales, 1993 2004
Trends in deaths related to drug misuse in, 1993 24 Oliver Morgan, Office for National Statistics and Imperial College London, Clare Griffiths, Barbara Toson and Cleo Rooney, Office for, Azeem Majeed,More information
Developments in the Norwegian overdose situation
Developments in the Norwegian overdose situation Thomas Clausen Professor (Dr. med) firstname.lastname@example.com 16.-18. October 2013 Agenda The overdose-situation Development and trends National responsesMore information
Effectiveness of Treatment The Evidence
Effectiveness of Treatment The Evidence The treatment programme at Castle Craig is based on the 12 Step abstinence model. This document describes the evidence for residential and 12 Step treatment programmes.More information
AUSTRALIAN T R E A T M E N T OU T C O M E STUDY - N S W Funded by the National Health and Medical Research Council and the Australian Government Department of Health. ATOS NSW is a project of the CentreMore information
Hard drug use in Norway
ELLEN J. AMUNDSEN & ANNE LINE BRETTEVILLE-JENSEN Overview Hard drug use in Norway S U M M A RY E.J. Amundsen & A. Bretteville-Jensen: Hard drug use in Norway Introduction Hard drug use has a variety ofMore information
To detox or not to detox: whose choice is it anyway? Dr Ed Day Senior Lecturer in Addiction Psychiatry University of Birmingham
To detox or not to detox: whose choice is it anyway? Dr Ed Day Senior Lecturer in Addiction Psychiatry University of Birmingham What do people say they want? Luty J (2004) 104 people attending a communityMore information
The National Community Detoxification Pilot
The National Community Detoxification Pilot Aoife Dermody, Progression Routes Initiative NDCI, 2011 Community Detoxification Protocols Guidelines for outpatient detoxification from methadone or benzodiazepinesMore information
HIGH SUCCESS RATE OF BUTTERY REHABILITATION PROGRAMS By treating addiction and helping people live productive, fulfilling lives, The Buttery addresses a major social and economic problem facing our society.More information
The NJSAMS Report. Heroin Admissions to Substance Abuse Treatment in New Jersey. In Brief. New Jersey Substance Abuse Monitoring System.
New Jersey Substance Abuse Monitoring System The NJSAMS Report May 2011 Admissions to Substance Abuse Treatment in New Jersey eroin is a semi-synthetic opioid drug derived from morphine. It has a highMore information
Drugs: education, prevenc on and policy, April 2008; 15(2): 211-218 informa healthcare Family carers and the prevention of heroin overdose deaths: Unmet training need and overlooked intervention opportunityMore information
Implementation of Systematic Programs of Overdose Training at Drug Treatment and Prevention Centres in Catalonia, 2008 2013
Implementation of Systematic Programs of Overdose Training in Catalonia 2008 2013 83 Implementation of Systematic Programs of Overdose Training at Drug Treatment and Prevention Centres in Catalonia, 2008More information
Variations in treatment organisation, practices and outcomes within the Norwegian Opioid Maintenance Treatment Programme
Norsk Epidemiologi 2011; 21 (1): 113-118 113 Variations in treatment organisation, practices and outcomes within the Norwegian Opioid Maintenance Treatment Programme Linn Gjersing 1, Helge Waal 1, Jo RøislienMore information
Abstinence and drug abuse treatment: Results from the Drug Outcome Research in Scotland study
Drugs: education, prevention and policy, December 2006; 13(6): 537 550 Abstinence and drug abuse treatment: Results from the Drug Outcome Research in Scotland study NEIL MCKEGANEY 1, MICHAEL BLOOR 1, MICHELEMore information
Recovery Outcomes for Opiate Users. FRN Research Report November 2013
Recovery Outcomes for Opiate Users FRN Research Report November 2013 Introduction Opiate use in America is at epidemic levels. The latest surveys show 4.5 million Americans using prescription painkillersMore information
The natural history of opiate dependence; findings from longterm follow-up studies. Jack Leach
The natural history of opiate dependence; findings from longterm follow-up studies Jack Leach Value of long- term follow-up studies Methodological problems Review of studies What they seem to tell us Value?More information
4. How does your city fit into the political-administrative structure of your country? Total Partial None. 5. Demographics
. City.Country. Official responsible for providing this information (mandatory) a. Name b. Position Official title c. Institution Name of the institution where you work d. Address Complete postal addressMore information
Hard drug use in Norway. Ellen J. Amundsen 1, Anne Line Bretteville-Jensen 1. Norway. Corresponding author:
1 This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Nordisk alkohol- & narkotikatidskrift with the title: Hard drug use in Norway following peer review. The definitiveMore information
Rationale for and approach to treating Opiate Use Disorders
Rationale for and approach to treating Opiate Use Disorders Gavin Bart, MD PhD FACP DFASAM Director, Division of Addiction Medicine Department of Medicine Hennepin County Medical Center Associate ProfessorMore information
drug treatment in england: the road to recovery
The use of illegal drugs in England is declining; people who need help to overcome drug dependency are getting it quicker; and more are completing their treatment and recovering drug treatment in ENGlaND:More information
Clinical profiles of cannabis-dependent adolescents in residential substance use treatment
bulletin Clinical profiles of cannabis-dependent adolescents in residential substance use treatment Anthony Arcuri, Jan Copeland and John Howard Key points Young people are most likely to present to residentialMore information
Treatment of opioid use disorders
Treatment of opioid use disorders Gerardo Gonzalez, MD Associate Professor of Psychiatry Director, Division of Addiction Psychiatry Disclosures I have no financial conflicts to disclose I will review evidenceMore information
Overdoses among friends: Drug users are willing to administer naloxone to others
Journal of Substance Abuse Treatment 30 (2006) 129 133 Overdoses among friends: Drug users are willing to administer naloxone to others Tara Lagu, (M.D.), Bradley J. Anderson, (Ph.D), Michael Stein, (M.D.)4,1More information
Abstinence versus agonist maintenance treatment: an outdated debate?
Abstinence versus agonist maintenance treatment: an outdated debate? Ambros Uchtenhagen After two decades of increasing acceptance and availability of agonist maintenance therapies, we hear more aboutMore information
Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio
Governor s Cabinet Opiate Action Team Promoting Wellness and Recovery John R. Kasich, Governor Tracy J. Plouck, Director Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio November 14,More information
Does referral from an emergency department to an. alcohol treatment center reduce subsequent. emergency room visits in patients with alcohol
Does referral from an emergency department to an alcohol treatment center reduce subsequent emergency room visits in patients with alcohol intoxication? Robert Sapien, MD Department of Emergency MedicineMore information
Addressing Alcohol and Drugs in the Community. Cabinet member: Cllr Keith Humphries - Public Health and Protection Services
Wiltshire Council Cabinet 17 April 2012 Subject: Addressing Alcohol and Drugs in the Community Cabinet member: Cllr Keith Humphries - Public Health and Protection Services Key Decision: Yes Executive SummaryMore information
Clinical Priorities for Alcohol and Drugs in Public Health
Clinical Priorities for Alcohol and Drugs in Public Health What do we need to Measure up to? Dr Michael Kelleher Clinical Lead Alcohol and Drugs Team, Health and Wellbeing Directorate SMMGP 8 th PrimaryMore information
Costing report. Drug misuse: psychosocial interventions and opioid detoxification. Implementing NICE guidance. July 2007
Drug misuse: psychosocial interventions and opioid detoxification Costing report Implementing NICE guidance July 2007 NICE clinical guidelines 51 and 52 National costing report: Drug misuse guidelinesMore information
Universities of Leeds, Sheffield and York http://eprints.whiterose.ac.uk/
promoting access to White Rose research papers Universities of Leeds, Sheffield and York http://eprints.whiterose.ac.uk/ This is an author produced version of a paper published in Journal of SubstanceMore information
2013 to 2002 States: United the in Use Heroin in Trends National Survey on Drug Use and Health Short Report April 23, 2015 TRENDS IN HEROIN USE IN THE UNITED STATES: 2002 TO 2013 AUTHORS Rachel N. Lipari,More information
Substance Abuse 2014-2015. Chapter 10: Substance Abuse
Substance Abuse 214-215 Chapter 1: Substance Abuse 265 214-215 Health of Boston Substance Abuse Substance abuse involves the excessive use of alcohol or illicit substances (e.g., marijuana, cocaine, heroin,More information
Opiate Dependence EPIDEMIOLOGY OF OPIATE USE Difficult to estimate true extent of opiate dependence Based on National Survey of Health and Mental Well Being: 1.2% sample used opiates in last 12 monthsMore information
Treatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call 1-800-662-HELP(4357)More information
FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma
FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma Background A growing opiate abuse epidemic has highlighted the need for effective treatment options. This study documentsMore information
National Addiction Centre, Maudsley Hospital/Institute of Psychiatry, King s College London, London, UK
RESEARCH REPORT doi:10.1111/j.1360-0443.2007.02050.x Attendance at Narcotics Anonymous and Alcoholics Anonymous meetings, frequency of attendance and substance use outcomes after residential treatmentMore information
Overdose Prevention and Naloxone Prescription for Opioid Users in San Francisco
Journal of Urban Health: Bulletin of the New York Academy of Medicine doi:10.1007/s11524-010-9495-8 * 2010 The Author(s). This article is published with open access at Springerlink.com Overdose PreventionMore information
NTORS After Five Years
NTORS After Five Years The National Treatment Outcome Research Study Changes in substance use, health and criminal behaviour during the five years after intake Michael Gossop, John Marsden and Duncan StewartMore information
Naloxone: Overview, Criminal Justice and other Special Settings
Naloxone: Overview, Criminal Justice and other Special Settings Ingrid Binswanger, MD, MPH, MS Division of General Internal Medicine Affiliated Member, Division of Substance Dependence University of ColoradoMore information
Care Management Council submission date: August 2013. Contact Information
Clinical Practice Approval Form Clinical Practice Title: Acute use of Buprenorphine for the Treatment of Opioid Dependence and Detoxification Type of Review: New Clinical Practice Revisions of ExistingMore information
THE EVALUATION OF PSYCHOANALYTICALLY INFORMED TREATMENT PROGRAMS FOR SEVERE PERSONALITY DISORDER: A CONTROLLED STUDY Marco Chiesa & Peter Fonagy
THE EVALUATION OF PSYCHOANALYTICALLY INFORMED TREATMENT PROGRAMS FOR SEVERE PERSONALITY DISORDER: A CONTROLLED STUDY Marco Chiesa & Peter Fonagy Aims Summary The aim of this study was to compare the effectivenessMore information
John R. Kasich, Governor Orman Hall, Director
John R. Kasich, Governor Orman Hall, Director 2 3 Epidemics of unintentional drug overdoses in Ohio, 1979-2011 1,2,3 1800 1600 1400 1200 1000 800 Prescription drugs are causing a larger overdose epidemicMore information
Treatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction [NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please callMore information
Effective treatment is available for people who have a powder-cocaine problem seven in ten of those who come into treatment either stop using or reduce their use substantially within six months POWDERMore information
Responsible management and use of a personal take-home naloxone supply: A pilot project
Drugs: education, prevention and policy, August 2010; 17(4): 388 399 ORIGINAL ARTICLE Responsible management and use of a personal take-home naloxone supply: A pilot project ANDREW MCAULEY 1, GEORGE LINDSAYMore information
Developing the Guernsey treatment system for substance misusers: Phases One and Two. Helen Baldwin Linda Prickett Adam Marr Jim McVeigh
Developing the Guernsey treatment system for substance misusers: Phases One and Two Helen Baldwin Linda Prickett Adam Marr Jim McVeigh Roles and responsibilities of the LJMU research team Helen BaldwinMore information
ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines - 2015
The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the leastMore information
The story of drug treatment
EFFECTIVE TREATMENT CHANGING LIVES www.nta.nhs.uk www.nta.nhs.uk 1 The story of drug treatment The use of illicit drugs is declining in England; more and more people who need help with drug dependencyMore information
How can we prevent heroin/opiate overdose deaths?: the contribution of pre-provided naloxone
How can we prevent heroin/opiate overdose deaths?: the contribution of pre-provided naloxone Professor John Strang National Addiction Centre, London, UK Declaration (personal & institutional) DH, NTA,More information
DMRI Drug Misuse Research Initiative
DMRI Drug Misuse Research Initiative Executive Summary Dexamphetamine Substitution as a Treatment of Amphetamine Dependence: a Two-Centre Randomised Controlled Trial Final Report submitted to the DepartmentMore information
The relationship among alcohol use, related problems, and symptoms of psychological distress: Gender as a moderator in a college sample
Addictive Behaviors 29 (2004) 843 848 The relationship among alcohol use, related problems, and symptoms of psychological distress: Gender as a moderator in a college sample Irene Markman Geisner*, MaryMore information
OPTUM By United Behavioral Health OPTUM GUIDELINE EVIDENCE BASE: Level of Care Guidelines
OPTUM By United Behavioral Health OPTUM GUIDELINE EVIDENCE BASE: Level of Care Guidelines Guideline Evaluation and Treatment Planning Discharge Planning Admission Criteria Continued Stay Criteria DischargeMore information
Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study
Drug and Alcohol Dependence 62 (2001) 255 264 www.elsevier.com/locate/drugalcdep Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National TreatmentMore information
Corl Kerry - Referral and Assessment for Residential Treatment (Tier 4) Introduction Types of Tier 4 Services Services provided at Tier 4
Corl Kerry - Referral and Assessment for Residential Treatment (Tier 4) This document seeks to name the criteria that can guide referrals to residential tier 4 facilities (Part A). It provides guidanceMore information
Special Populations in Alcoholics Anonymous. J. Scott Tonigan, Ph.D., Gerard J. Connors, Ph.D., and William R. Miller, Ph.D.
Special Populations in Alcoholics Anonymous J. Scott Tonigan, Ph.D., Gerard J. Connors, Ph.D., and William R. Miller, Ph.D. The vast majority of Alcoholics Anonymous (AA) members in the United States areMore information
YOUNG ADULTS IN DUAL DIAGNOSIS TREATMENT: COMPARISON TO OLDER ADULTS AT INTAKE AND POST-TREATMENT Siobhan A. Morse, MHSA, CRC, CAI, MAC Director of Fidelity and Research Foundations Recovery Network YOUNGMore information
Overview of the Breaking Free research and evaluation programme. Based on the MRC framework for developing and evaluating complex interventions
Overview of the Breaking Free research and evaluation programme Based on the MRC framework for developing and evaluating complex interventions June 2015 1 Overview of the Breaking Free research and evaluationMore information
Treatment of Alcoholism
Treatment of Alcoholism Why is it important Prevents further to body by getting people off alcohol. Can prevent death. Helps keep health insurance down. Provides assistance so alcoholics don t t have toMore information
Outcomes for Opiate Users at FRN Facilities. FRN Research Report September 2014
Outcomes for Opiate Users at FRN Facilities FRN Research Report September 2014 Introduction The illicit use of opioids has reached epidemic proportions in the United States (Alford, 2007; Meges et al,More information
Does take home naloxone fulfill the Bradford Hill criteria for effectiveness? A systematic review. Rebecca McDonald PhD student Addictions Department
Does take home naloxone fulfill the Bradford Hill criteria for effectiveness? A systematic review Rebecca McDonald PhD student Addictions Department Overview 1. Introduction: opioid overdose deaths andMore information
1 THE DRUG DETOX UNIT AT MOUNTJOY PRISON A REVIEW By Dr. Des Crowley, General Practitioner INTRODUCTION The Drug Detox Unit was opened in July 1996 at Mountjoy Prison in response to the escalating drugMore information
Foundations Recovery Network (FRN) Announces Groundbreaking Opiate Research Study Which Yields Compelling Results
Foundations Recovery Network (FRN) Announces Groundbreaking Opiate Research Study Which Yields Compelling Results Results validate FRN s system of care approach through patient satisfaction Siobhan A.More information
REVIEW OF DRUG TREATMENT AND REHABILITATION SERVICES: SUMMARY AND ACTIONS 1. INTRODUCTION 1.1 Review Process A Partnership for a Better Scotland committed the Scottish Executive to reviewing and investingMore information
ORGANIZATION OF AMERICAN STATES INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION FIRST INTER-REGIONAL FORUM OF EU-LAC CITIES: PUBLIC POLICIES IN DRUG TREATMENT April 2 5, 2008 Santo Domingo, Dominican RepublicMore information
Executive Summary. 1. What is the temporal relationship between problem gambling and other co-occurring disorders?
Executive Summary The issue of ascertaining the temporal relationship between problem gambling and cooccurring disorders is an important one. By understanding the connection between problem gambling andMore information
Alcohol Addiction. Introduction. Overview and Facts. Symptoms
Alcohol Addiction Alcohol Addiction Introduction Alcohol is a drug. It is classed as a depressant, meaning that it slows down vital functions -resulting in slurred speech, unsteady movement, disturbedMore information
Testimony of The New York City Department of Health and Mental Hygiene. before the
Testimony of The New York City Department of Health and Mental Hygiene before the New York City State Assembly Committee on Alcoholism and Drug Abuse on Programs and Services for the Treatment of OpioidMore information
Effects of Distance to Treatment and Treatment Type on Alcoholics Anonymous Attendance and Subsequent Alcohol Consumption. Presenter Disclosure
Effects of Distance to Treatment and Treatment Type on Alcoholics Anonymous Attendance and Subsequent Alcohol Consumption Jamie L. Heisey, MA Katherine J. Karriker-Jaffe, PhD Jane Witbrodt, PhD Lee AnnMore information
Journal of Psychiatric Intensive Care Vol.0 No.0:1 6 doi:10.1017/s1742646410000087 Ó NAPICU 2010. Original Article. Abstract.
Journal of Psychiatric Intensive Care Journal of Psychiatric Intensive Care Vol.0 No.0:1 6 doi:10.1017/s1742646410000087 Ó NAPICU 2010 Original Article Diagnosis after an acute psychiatric inpatient stay:More information
Heroin in Snohomish County: Mortality and Treatment Trends
Heroin in Snohomish County: Mortality and Treatment Trends January 2015 This page left intentionally blank. Table of Contents Introduction and Acknowledgments 1 Executive Summary 2 Mortality Overdose MortalityMore information
Utilization of the Electronic Medical Record to Assess Morbidity and Mortality in Veterans Treated for Substance Use Disorders
Utilization of the Electronic Medical Record to Assess Morbidity and Mortality in Veterans Treated for Substance Use Disorders Dr. Kathleen P. Decker, M.D. Staff Psychiatrist, Hampton VAMC Assistant Professor,More information
Joint Committee on Health and Children
Houses of the Oireachtas Joint Committee on Health and Children A Submission From Homeless & Drugs Services Homeless & Drugs Services September 15 th 2011 1 CONTENTS Page no. 0.1 Introduction 3 0.2 StructureMore information
Adult ADHD Service - 5 BP. Dr Joe Johnson Consultant Psychiatrist Five Boroughs Partnership NHS Trust
Adult ADHD Service - 5 BP Dr Joe Johnson Consultant Psychiatrist Five Boroughs Partnership NHS Trust My Background Consultant Psychiatrist in 5BP since 2005 Working both in Community and Prison MH (Risley)More information
4. Meier, P. & Best, D. (2006) Programme factors that influence completion of residential treatment. Drug and Alcohol Review, 25, 349-355.
DAVID BEST PUBLICATIONS 2006-2011 2006 1. Best, D., Havis, S., Payne-James, J. & Stark, M. (2006) Near miss incidents in police custody suites in 2003: A feasibility study, Journal of Clinical ForensicMore information
First on the Scene: People Who Use Drugs, their Families and their Friends. Sharon Stancliff, MD, FAAFP Harm Reduction Coalition New York, NY
First on the Scene: People Who Use Drugs, their Families and their Friends Sharon Stancliff, MD, FAAFP Harm Reduction Coalition New York, NY A brief history with a common theme Chicago 1996: Chicago RecoveryMore information
Treatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective
Treatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective Dale K. Adair, MD Medical Director/Chief Psychiatric Officer OMHSAS 1 Treatment and Interventions forMore information
Course Description. SEMESTER I Fundamental Concepts of Substance Abuse MODULE OBJECTIVES
Course Description SEMESTER I Fundamental Concepts of Substance Abuse MODULE OBJECTIVES At the end of this course participants will be able to: Define and distinguish between substance use, abuse and dependenceMore information
National Treatment Agency for Substance Misuse Long-term results for those who have been treated in one year found that nearly half who leave neither need further treatment nor were found to be involvedMore information
Alcohol and Re-offending Who Cares?
January 2004 Alcohol and Re-offending Who Cares? This briefing paper focuses on the high level of alcohol misuse and dependence within the prison population. In recent years a great deal of time and moneyMore information
Metropolitan Detention Center (MDC) DWI Addiction Treatment Programs (ATP) Outcome Study for DWI Offenders
Metropolitan Detention Center (MDC) DWI Addiction Treatment Programs (ATP) Outcome Study for DWI Offenders Prepared for: The DWI Addiction Treatment Programs (ATP) Metropolitan Detention Center PreparedMore information
Current Model of Drug Care. Components of a Full Drug Care Service
Current Model of Drug Care Treatment Detox Rehab Components of a Full Drug Care Service (1) (2) (3) (4) (5) (6) (7) (8) (9) Community Preparation Treatment Detox Rehab Community Community Prison work HalfwayMore information
Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery
Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery Marvin D. Seppala, MD Chief Medical Officer Hazelden Betty Ford Foundation This product is supported byMore information
Intake Consultation and Assessment Before Detox. What Happens During Drug Detox?
What Happens During Drug Detox? Many addicts and alcoholics believe they can quit using substances on their own. But after a few painful and confidence-crushing failed attempts, the need for an inpatientMore information
Jennifer Sharpe Potter, PhD, MPH Associate Professor Division of Alcohol and Drug Addiction Department of Psychiatry
Buprenorphine/Naloxone and Methadone Maintenance Treatment Outcomes for Opioid Analgesic, Heroin, and Combined Users: Findings From Starting Treatment With Agonist Replacement Therapies (START) JenniferMore information
The extent and nature of mental health issues among problem drug users and issues in treatment.
The extent and nature of mental health issues among problem drug users and issues in treatment. Well, that rules out a coalition DIAGNOSIS? Diagnosis implies identifiable clinical picture Often associatedMore information
E THE SUBSTANCE ABUSE TREATMENT SYSTEM: WHAT DOES IT LOOK LIKE AND WHOM DOES IT SERVE? Preliminary Findings from the Alcohol and Drug Services Study Constance M. Horgan and Helen J. Levine Institute forMore information
AMA from Detox Learning Collaborative
January 25, 2013 BEACON HEALTH STRATEGIES beaconhealthstrategies.com February 22, 2013 1 Agenda 1. Introductions 2. Overview of the project 3. 2012 Western NY Medicaid Fee for Service (FFS) Data AnalysisMore information
Objectives. Background
Development and Implementation of a Pharmacist-Managed Intranasal Naloxone Distribution Program in a Veterans Affairs Healthcare Facility and Associated Community Clinics Innovative Practices Award FinalistMore information
Predictors of Substance Abuse Treatment Engagement among Rural Appalachian Prescription Drug Users
Predictors of Substance Abuse Treatment Engagement among Rural Appalachian Prescription Drug Users Jennifer R. Havens, PhD, MPH Carrie B. Oser, PhD Carl G. Leukefeld, PhD Study Objective The objectiveMore information
The efficacy of a relapse prevention programme in the treatment of heroin dependence in China
The efficacy of a relapse prevention programme in the treatment of heroin dependence in China Zhao Min 1, Li Xu 1, Wang Zhu-cheng 1, Xu Ding 2, Zhang Yi 2, Zhang Ming-yuang 1 1 Shanghai Mental Health CentreMore information
HOW TO APPLY AND PREPARE FOR LICENSURE TO OPERATE A SUBSTANCE ABUSE PROGRAM IN MICHIGAN Authority: P.A. 368 of 1978, as amended
LARA/SUB-501 (5/13) Michigan Department of Licensing and Regulatory Affairs Bureau of Health Care Services Health Facilities Division Substance Abuse Program P.O. Box 30664 Lansing, MI 48909 PHONE: (517)More information
Specialist drug and alcohol services for young people a cost benefit analysis
Research Report DFE-RR087 Specialist drug and alcohol services for young people a cost benefit analysis Frontier Economics This research report was commissioned before the new UK Government took officeMore information
Adult drug treatment plan 2009/10. Part 1: Strategic summary, needs assessment and key priorities
Birmingham Drug and Alcohol Action Team Adult drug treatment plan 2009/10 Part 1: Strategic summary, needs assessment and key priorities The strategic summary incorporating the findings of the needs assessment,More information
1. Youth Drug Use More than 40% of Maryland high school seniors used an illicit drug in the past year.
1. Youth Drug Use More than 4% of Maryland high school seniors used an illicit drug in the past year. Any Illicit Drug Alcohol Marijuana Ecstasy Cocaine Percentage of Maryland and U.S. high school seniorsMore information
Fairfax-Falls Church Community Services Board
LOB #267: ADULT RESIDENTIAL TREATMENT SERVICES Purpose Adult Residential Treatment Services provides residential treatment programs for adults with severe substance use disorders and/or co occurring mentalMore information
PERSPECTIVES ON DRUGS The role of psychosocial interventions in drug treatment
UPDATED 4.6.2015 PERSPECTIVES ON DRUGS The role of psychosocial interventions in drug treatment Psychosocial interventions are structured psychological or social interventions used to address substance-relatedMore information


text:
Join Our Affiliate Program
Add value to your website by joining the ColaStuffUSA.com Affiliate Program. Our program will earn you a generous commission on every sale referred from your site, plus provide your users with access to Coca-Cola® Brand Merchandise, the #1 collectible in the world.
As part of the ColaStuffUSA.com Affiliate Program, you can earn up to 10% commission on each product sold through your website.
how it works
The ColaStuffUSA.com Affiliate Program allows you to make money by referring cus
tomers to ColaStuffUSA.com web site. Every time you refer a customer to us and that
customer makes a purchase on ColaStuffUSA.com you earn a commission. We ha
ndle transaction processing, fulfillment and customer service. You make a commission on every sale. ColaStuffUSA.com has partnered with ClixGalore Interface to make it easy for you to become a ColaStuffUSA.com affiliate. We provide you with all the tools you need to become an affiliate. By partnering with ColaStuffUSA.com, a premier supplier of Coca-Cola® licensed gifts, collectibles and home decor, affiliates can choose to promote top products, or include banners or search boxes that directly link to ColaStuffUSA.com on their blog or website.
how to join
Joining our affiliate program is easy and free! Simply fill out our online registration form:
We will contact you once we have reviewed and approved your site. If you have any questions about our program or would like more information, please contact us at: firstname.lastname@example.com.
US, UK, AU, CA Web sites and affiliates at this time.
- Coca-Cola Caps, Hats & Visors
- Coca-Cola® Tee Shirts, HOODIES AND Sweatshirts
- Coca-Cola Winter Apparel Accessories
- Coca-Cola® Totes, Purses , Wallets and more!
- Coca-Cola® Anniversary & Collectible Bottles
- Coca-Cola® Games & Puzzles
- Coca-Cola® Tins/Lunchboxes
- Coca-Cola® Jewelry
- Coca-Cola Kitchen Items & Tableware
- Coca-Cola® Refrigerators, Lunch Bags & Coolers
- Coca-Cola® Cars, Trucks, and More!
- Coca-Cola® Kitchen Towels, Placemats & Aprons
- Coca-Cola® BOYDS Bears & Limited Gifts
- Coca-Cola® Trays
- Coca-Cola Ladies Wear
- Coca-Cola Clocks & Neon Signs
- Coca-Cola Office & School
- Coca-Cola Patio Umbrellas & Outdoor Decor
- Coca-Cola Pet Accessories
- Coca-Cola Salt/Pepper Sets
- Coca-Cola "STUFF"
- Coca-Cola® Diner Furniture
- Coca-Cola® Bed & Bath Items
- Coca-Cola® Metal Signs & Menu Boards

subset: commoncrawl